Alnylam Pharmaceuticals, Inc.

ALNYintermediary

Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating disease by silencing the genes that cause it. Its ATTR franchise has established RNAi as a validated drug modality, and its deep pipeline across cardiometabolic, CNS, and infectious diseases promises to expand the platform's reach.

共有:

⇄ Compare

製品と売上

製品別売上シェア

売上内訳 ($2.4B)

静的データ（リアルタイム財務ロード中…）

ATTR Franchise (Amvuttra/Onpattro) (65%)

Royalties & Collaboration (Leqvio) (25%)

Other Pipeline Revenue (10%)

セグメント構成と主要顧客

製品詳細

Onpattro (Patisiran)30%

First FDA-approved RNAi therapeutic for hereditary ATTR amyloidosis

Amvuttra (Vutrisiran)40%

Subcutaneous RNAi treatment for ATTR polyneuropathy (quarterly dosing)

Leqvio (Inclisiran)30%

RNAi cholesterol-lowering drug partnered with Novartis

サプライチェーン関係

パートナー

Regeneron Pharmaceuticals

RNAi research collaboration

影響: Strategic R&D alliance

Eli Lilly and Company

Potential licensing discussions

影響: Pharma partnership potential

競合他社

Moderna, Inc.

RNA-based therapeutic modalities

影響: Competing RNA platforms

マクロ・市場概況

제약 / 바이오セクターニュース

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

次の主要イベント

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI分析

Alnylam Pharmaceuticals, Inc.のAIサプライチェーン分析を受けるには「AI分析を取得」をクリックしてください。

企業情報

本社所在地

Cambridge, Massachusetts, USA

設立

2002

従業員数

2,800+

ウェブサイト

alnylam.com

セクター概況 — 제약 / 바이오

セクターニュース